Phase 1 study of IMGN853, a folate receptor alpha (FRα)targeting antibodydrug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRApositive solid tumors

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2015
This article has no abstract
Epistemonikos ID: 6aac2a82cfffd4d3479ddf0482ba54b7ec6a21b7
First added on: Feb 07, 2025